Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

On February 23 2017, Cocrystal Pharma, Inc. (the “Company”) entered into an agreement with James J. Martin to serve as the interim Chief Financial Officer of the Company as an independent contractor beginning February 27, 2017. Mr. Martin will be compensated $125 per hour up to a maximum of $7,500 per week.
Mr. Martin, 50, has served as Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTCPink:NIMU) since January 2011. Since November 2016, he has served as Chief Financial Officer of Motus GI Holdings, Inc, a privately held medical device company. From September 2014 to November 2016 Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (NASDAQ: VBIV), a pharmaceutical development and manufacturing company. From April 2014 to September 2015, Mr. Martin served as Chief Financial Officer of Vapor Corp, Inc. (NASDAQ: VPCO), a vaporizer retail and wholesale company. From January 2011 to October 2, 2013, Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc.
Previously, on February 8, 2017, the Company had entered an agreement with Craig Hooson, a financial consultant with Tatum LLC, to serve as the Company’s interim Chief Financial Officer. The Company delayed reporting Mr. Hooson’s appointment on Form 8-K pending its planned issuance of a press release. However, on February 17, 2017, prior to beginning his work for the Company, Mr. Hooson withdrew his acceptance of the Company’s offer.
Item 9.01
Financial Statements and Exhibits

(d) Exhibits.
Exhibit No.
Exhibit

10. 1
James Martin Consulting Agreement


About Cocrystal Pharma, Inc. (OTCBB:COCP)

Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information.

Cocrystal Pharma, Inc. (OTCBB:COCP) Recent Trading Information

Cocrystal Pharma, Inc. (OTCBB:COCP) closed its last trading session down -0.034 at 0.281 with 791,135 shares trading hands.